Physician
Analytic Pathology Medical Group INC.
Analytic Pathology Medical Group INC. was paid $16.75M by Medicaid between Jan 2018 and Nov 2024, across 245 billing codes. Its largest line is 87636, Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B — 25% of everything it billed.
33Billing provider infoANALYTIC PATHOLOGY MEDICAL GROUP INC.
LA MESA, CA 91942
LA MESA, CA 91942
33aNPI1568431088assigned 03/16/2006
33bProvider typeCytopathology Physician
28Total paid$16.75M
24GClaims4,766,388
24DCodes billed245
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other Cytopathology Physician providers in California
Rank by total paid#2 of 69
Median peer was paid$50K
This provider vs. median333×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 823,784 | $2.06M | |
| 2019 | 711,997 | $1.89M | |
| 2020 | 531,578 | $1.55M | |
| 2021 | 597,587 | $1.78M | |
| 2022 | 832,742 | $3.60M | |
| 2023 | 795,543 | $3.56M | |
| 2024incomplete | 473,157 | $2.31M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | 25% | 43,479 | 41,525 | $4.12M |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 7.1% | 34,271 | 33,160 | $1.19M |
| 80053 | Comprehensive metabolic panel | 6.7% | 637,323 | 422,437 | $1.12M |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 6.1% | 739,706 | 457,248 | $1.02M |
| 88307 | 5.6% | 13,461 | 13,374 | $944K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 5.6% | 16,762 | 15,582 | $941K |
| 82962 | 4.3% | 150,076 | 57,455 | $714K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 2.3% | 5,440 | 5,291 | $390K |
| 83735 | 1.8% | 255,173 | 117,369 | $305K | |
| 84484 | 1.7% | 142,477 | 122,012 | $280K | |
| 88304 | 1.6% | 12,558 | 12,473 | $268K | |
| 80048 | Basic metabolic panel (calcium, ionized) | 1.6% | 182,035 | 79,636 | $267K |
233 more codes
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.5% | 8,616 | $250K |
| 83880 | 1.5% | 41,356 | $243K | |
| 87040 | 1.2% | 59,804 | $204K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 1.2% | 41,513 | $201K |
| 80061 | Lipid panel | 1.1% | 82,744 | $188K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | 1.1% | 6,919 | $186K |
| 84443 | Thyroid stimulating hormone (TSH) | 1.0% | 59,639 | $173K |
| 87641 | 1.0% | 25,568 | $168K | |
| 83690 | <1% | 138,530 | $157K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 22,684 | $134K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 22,838 | $130K |
| 85027 | <1% | 104,253 | $120K | |
| 84145 | <1% | 27,888 | $118K | |
| 83605 | <1% | 53,331 | $108K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 2,528 | $105K |
| 85610 | <1% | 139,330 | $100K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 8,272 | $95K |
| 85730 | <1% | 77,826 | $95K | |
| 84100 | <1% | 113,928 | $94K | |
| 81001 | <1% | 173,609 | $92K | |
| 84702 | <1% | 38,070 | $88K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 46,853 | $79K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,844 | $73K |
| 87186 | <1% | 35,434 | $67K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 47,784 | $67K |
| 88342 | <1% | 2,076 | $65K | |
| 87077 | <1% | 37,836 | $64K | |
| 80074 | <1% | 8,231 | $64K | |
| 87070 | <1% | 39,145 | $59K | |
| 87486 | <1% | 7,558 | $50K | |
| 87581 | <1% | 7,554 | $50K | |
| 85379 | <1% | 26,830 | $46K | |
| 87088 | <1% | 39,060 | $44K | |
| 81000 | <1% | 83,822 | $42K | |
| 84703 | <1% | 32,811 | $36K | |
| 86900 | <1% | 74,895 | $36K | |
| 86780 | <1% | 15,979 | $35K | |
| 82550 | <1% | 30,169 | $34K | |
| 87480 | <1% | 10,162 | $34K | |
| 87510 | <1% | 10,161 | $34K | |
| 87660 | <1% | 10,164 | $34K | |
| 88302 | <1% | 1,272 | $33K | |
| 86901 | <1% | 67,527 | $32K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 10,604 | $32K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 8,712 | $32K |
| 82140 | <1% | 12,715 | $32K | |
| 80076 | <1% | 25,081 | $31K | |
| 88189 | <1% | 668 | $31K | |
| 87205 | <1% | 35,176 | $27K | |
| 82077 | <1% | 1,999 | $26K | |
| 80202 | <1% | 10,590 | $25K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 18,779 | $23K |
| 88341 | <1% | 548 | $23K | |
| 82728 | <1% | 9,358 | $22K | |
| 83550 | <1% | 14,964 | $21K | |
| 82570 | <1% | 22,024 | $21K | |
| 88112 | <1% | 1,132 | $20K | |
| 83540 | <1% | 16,843 | $19K | |
| 84439 | <1% | 12,390 | $19K | |
| 89051 | <1% | 4,187 | $18K | |
| 80047 | <1% | 11,008 | $18K | |
| 87081 | <1% | 16,187 | $17K | |
| 83615 | <1% | 17,880 | $17K | |
| 86850 | <1% | 31,255 | $16K | |
| 83525 | <1% | 8,283 | $16K | |
| 87075 | <1% | 8,486 | $16K | |
| 84550 | <1% | 22,726 | $16K | |
| 88313 | <1% | 269 | $15K | |
| 82043 | <1% | 14,433 | $15K | |
| 87400 | <1% | 11,578 | $14K | |
| 87149 | <1% | 616 | $14K | |
| 87449 | <1% | 7,338 | $13K | |
| 87653 | <1% | 2,331 | $13K | |
| 81003 | <1% | 34,821 | $13K | |
| 85384 | <1% | 7,479 | $13K | |
| 83970 | <1% | 1,797 | $12K | |
| 82803 | <1% | 3,339 | $11K | |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 489 | $11K |
| 80069 | <1% | 7,115 | $11K | |
| 86922 | <1% | 869 | $10K | |
| 82553 | <1% | 4,049 | $10K | |
| 88300 | <1% | 1,786 | $10K | |
| 86762 | <1% | 3,868 | $9K | |
| 86480 | <1% | 801 | $9K | |
| 82330 | <1% | 2,907 | $9K | |
| 87631 | <1% | 757 | $8K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 324 | $8K |
| 85060 | <1% | 797 | $8K | |
| 83520 | <1% | 3,905 | $8K | |
| 82607 | <1% | 2,658 | $8K | |
| 80164 | <1% | 3,017 | $7K | |
| 80143 | <1% | 594 | $7K | |
| 84153 | <1% | 2,243 | $7K | |
| 84480 | <1% | 2,876 | $7K | |
| 86703 | <1% | 2,821 | $7K | |
| 80179 | <1% | 537 | $7K | |
| 86828 | <1% | 739 | $6K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 3,629 | $6K |
| 85018 | <1% | 13,216 | $6K | |
| 87045 | <1% | 3,638 | $6K | |
| 82746 | <1% | 2,297 | $6K | |
| 86880 | <1% | 6,057 | $6K | |
| 85007 | <1% | 10,510 | $5K | |
| 87427 | <1% | 2,904 | $5K | |
| 82805 | <1% | 706 | $5K | |
| 87640 | <1% | 865 | $5K | |
| 87324 | <1% | 2,905 | $5K | |
| 82009 | <1% | 6,693 | $5K | |
| 87102 | <1% | 2,853 | $5K | |
| 85652 | <1% | 10,330 | $5K | |
| 85378 | <1% | 4,284 | $5K | |
| 84436 | <1% | 3,997 | $5K | |
| 88360 | <1% | 59 | $4K | |
| 87116 | <1% | 1,041 | $4K | |
| 85651 | <1% | 8,845 | $4K | |
| 83930 | <1% | 3,258 | $4K | |
| 88311 | <1% | 923 | $4K | |
| 84300 | <1% | 4,304 | $4K | |
| 84481 | <1% | 1,235 | $4K | |
| 85045 | <1% | 5,048 | $3K | |
| 87147 | <1% | 4,259 | $3K | |
| 84478 | <1% | 4,836 | $3K | |
| 85014 | <1% | 7,440 | $3K | |
| 84156 | <1% | 4,953 | $3K | |
| 87015 | <1% | 2,200 | $3K | |
| 87206 | <1% | 2,360 | $3K | |
| 86832 | <1% | 1,387 | $3K | |
| 86833 | <1% | 1,397 | $3K | |
| 86977 | <1% | 886 | $3K | |
| 87210 | <1% | 4,230 | $3K | |
| 82150 | <1% | 2,441 | $3K | |
| 82247 | <1% | 3,618 | $3K | |
| 81025 | <1% | 2,295 | $3K | |
| 82270 | <1% | 4,790 | $3K | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 1,002 | $3K |
| 86708 | <1% | 999 | $2K | |
| 87340 | <1% | 1,204 | $2K | |
| 86580 | <1% | 656 | $2K | |
| 87046 | <1% | 3,683 | $2K | |
| 86431 | <1% | 1,913 | $2K | |
| 86308 | <1% | 2,316 | $2K | |
| 87420 | <1% | 3,138 | $2K | |
| 82248 | <1% | 2,162 | $2K | |
| 82731 | <1% | 160 | $2K | |
| 84132 | <1% | 2,376 | $2K | |
| 86235 | <1% | 120 | $2K | |
| 86140 | <1% | 1,654 | $2K | |
| 83935 | <1% | 1,206 | $2K | |
| 85097 | <1% | 65 | $2K | |
| 88173 | <1% | 43 | $1K | |
| 86141 | <1% | 666 | $1K | |
| 82378 | <1% | 433 | $1K | |
| 85670 | <1% | 1,351 | $1K | |
| 87493 | <1% | 241 | $1K | |
| 87899 | <1% | 1,298 | $1K | |
| 82657 | <1% | 316 | $1K | |
| 82977 | <1% | 967 | $1K | |
| 86803 | <1% | 429 | $1K | |
| 86038 | <1% | 500 | $997.94 | |
| 85044 | <1% | 1,954 | $991.92 | |
| 84157 | <1% | 1,670 | $990.56 | |
| 82542 | <1% | 315 | $942.82 | |
| 84295 | <1% | 905 | $862.67 | |
| 82945 | <1% | 1,226 | $808.88 | |
| 80178 | <1% | 534 | $802.47 | |
| 82010 | <1% | 495 | $735.23 | |
| 80197 | <1% | 246 | $730.54 | |
| 84681 | <1% | 197 | $695.86 | |
| 88312 | <1% | 25 | $641.83 | |
| 87185 | <1% | 2,126 | $630.44 | |
| 82533 | <1% | 197 | $618.89 | |
| 83630 | <1% | 182 | $597.92 | |
| 82565 | <1% | 751 | $591.27 | |
| 85390 | <1% | 223 | $540.93 | |
| 82951 | <1% | 246 | $535.93 | |
| 82105 | <1% | 50 | $515.17 | |
| 80320 | <1% | 3,416 | $499.40 | |
| 86787 | <1% | 203 | $448.58 | |
| 86870 | <1% | 143 | $426.20 | |
| 84165 | <1% | 265 | $375.03 | |
| 88104 | <1% | 31 | $374.22 | |
| 85347 | <1% | 437 | $370.14 | |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | <1% | 69 | $360.52 |
| 86830 | <1% | 146 | $354.32 | |
| 86831 | <1% | 146 | $354.32 | |
| 84075 | <1% | 700 | $347.51 | |
| 87209 | <1% | 114 | $342.34 | |
| 86376 | <1% | 125 | $322.66 | |
| 86160 | <1% | 103 | $318.74 | |
| 80185 | <1% | 123 | $300.33 | |
| 86706 | <1% | 178 | $300.03 | |
| 87807 | <1% | 299 | $297.40 | |
| 87632 | <1% | 15 | $276.73 | |
| 84520 | <1% | 465 | $260.49 | |
| 83516 | <1% | 108 | $247.01 | |
| 86225 | <1% | 91 | $217.91 | |
| 86592 | <1% | 333 | $210.93 | |
| 84540 | <1% | 263 | $200.04 | |
| 86147 | <1% | 28 | $187.46 | |
| 86704 | <1% | 95 | $178.97 | |
| 82947 | <1% | 313 | $175.37 | |
| 80051 | <1% | 184 | $173.08 | |
| 84134 | <1% | 67 | $156.34 | |
| 85049 | <1% | 622 | $151.03 | |
| 82374 | <1% | 427 | $117.98 | |
| 84450 | <1% | 141 | $117.47 | |
| 88108 | <1% | 13 | $117.19 | |
| 86593 | <1% | 147 | $116.69 | |
| 89190 | <1% | 33 | $115.25 | |
| 84460 | <1% | 139 | $113.60 | |
| 86301 | <1% | 29 | $102.47 | |
| 86060 | <1% | 82 | $101.54 | |
| 86800 | <1% | 26 | $73.17 | |
| 82784 | <1% | 41 | $53.18 | |
| 87106 | <1% | 24 | $51.83 | |
| 86705 | <1% | 26 | $51.75 | |
| 86403 | <1% | 27 | $50.12 | |
| 85460 | <1% | 37 | $44.23 | |
| 82436 | <1% | 45 | $37.97 | |
| 81015 | <1% | 74 | $34.70 | |
| 84166 | <1% | 12 | $33.37 | |
| 87177 | <1% | 24 | $32.80 | |
| 86334 | <1% | 13 | $30.88 | |
| 85461 | <1% | 39 | $29.72 | |
| 82310 | <1% | 73 | $29.39 | |
| 86765 | <1% | 12 | $27.48 | |
| 87220 | <1% | 24 | $17.83 | |
| 84155 | <1% | 36 | $15.63 | |
| 82040 | <1% | 46 | $14.81 | |
| 87176 | <1% | 12 | $12.90 | |
| 82435 | <1% | 52 | $12.04 | |
| 80329 | <1% | 755 | $6.10 | |
| 84479 | <1% | 46 | $2.27 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMENDOZA, ARTURO (DIRECTOR / CHIEF FINANCIAL OFFICER)
| Provider | Location | Paid |
|---|---|---|
| Pacific Rim Pathology Medical Corporation | San Diego, CA | $723K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.